IL235476B - Emitter/anti-emitter analogs are marked with f18 - Google Patents

Emitter/anti-emitter analogs are marked with f18

Info

Publication number
IL235476B
IL235476B IL235476A IL23547614A IL235476B IL 235476 B IL235476 B IL 235476B IL 235476 A IL235476 A IL 235476A IL 23547614 A IL23547614 A IL 23547614A IL 235476 B IL235476 B IL 235476B
Authority
IL
Israel
Prior art keywords
antifolate
analogues
folate
labelled
labelled folate
Prior art date
Application number
IL235476A
Other languages
English (en)
Hebrew (he)
Other versions
IL235476A0 (en
Original Assignee
Merck & Cie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Cie filed Critical Merck & Cie
Publication of IL235476A0 publication Critical patent/IL235476A0/en
Publication of IL235476B publication Critical patent/IL235476B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • C07D475/02Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • C07D475/06Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL235476A 2012-05-08 2014-11-03 Emitter/anti-emitter analogs are marked with f18 IL235476B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12167126 2012-05-08
PCT/EP2013/059584 WO2013167653A1 (en) 2012-05-08 2013-05-08 18f-labelled folate/antifolate analogues

Publications (2)

Publication Number Publication Date
IL235476A0 IL235476A0 (en) 2014-12-31
IL235476B true IL235476B (en) 2019-09-26

Family

ID=48407549

Family Applications (1)

Application Number Title Priority Date Filing Date
IL235476A IL235476B (en) 2012-05-08 2014-11-03 Emitter/anti-emitter analogs are marked with f18

Country Status (17)

Country Link
US (1) US10357576B2 (https=)
EP (1) EP2864329B1 (https=)
JP (1) JP6198814B2 (https=)
KR (1) KR102116000B1 (https=)
CN (1) CN104379585B (https=)
AU (1) AU2013258027B2 (https=)
CA (1) CA2870124C (https=)
DK (1) DK2864329T3 (https=)
EA (1) EA201401225A1 (https=)
ES (1) ES2703627T3 (https=)
IL (1) IL235476B (https=)
PL (1) PL2864329T3 (https=)
PT (1) PT2864329T (https=)
SG (1) SG11201406481TA (https=)
TR (1) TR201819802T4 (https=)
WO (1) WO2013167653A1 (https=)
ZA (1) ZA201407266B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101646577B1 (ko) * 2014-08-14 2016-08-09 원광대학교산학협력단 엽산수용체 표적용 화합물 또는 이의 약학적으로 허용가능한 염과, 이를 유효성분으로 포함하는 암 예방, 진단 또는 치료용 조성물
JP7204662B2 (ja) * 2017-03-20 2023-01-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 異性体的に純粋な18f-標識されたテトラヒドロ葉酸
EP3671511B1 (en) 2018-12-19 2022-07-06 Rohde & Schwarz GmbH & Co. KG Communication system and method
DE102019110904B4 (de) * 2019-04-26 2022-01-20 Helmholtz-Zentrum Dresden - Rossendorf E. V. N-(4-methoxy-7-morpholinobenzo[d]thiazol-2-yl)-acetamid-Derivate und deren Verwendung
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
SMT202500271T1 (it) 2020-07-02 2025-09-12 Incyte Corp Composti di urea triciclici come inibitori di v617f di jak2
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
CN119173514A (zh) 2022-03-17 2024-12-20 因赛特公司 作为jak2 v617f抑制剂的三环脲化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007128036A (ru) 2004-12-23 2009-01-27 Пердью Рисерч Фаундейшн (Us) Способ получения изображения позитронно-эмиссионной томографией
JP4503039B2 (ja) 2006-04-27 2010-07-14 三洋電機株式会社 回路装置
US8586595B2 (en) 2007-02-07 2013-11-19 Purdue Research Foundation Positron emission tomography imaging method
DK2150514T3 (en) 2007-04-11 2019-02-18 Merck & Cie 18F-LABELED FOLATES
WO2008125615A1 (en) 2007-04-11 2008-10-23 Merck Eprova Ag 18 f-labelled folates
CA2670363C (en) 2007-04-11 2015-07-21 Merck Eprova Ag 18f-labelled folates
US20100143249A1 (en) 2007-04-11 2010-06-10 Merck Eprova Ag Folate-conjugates and corresponding metal-chelate complexes for use in diagnostic imaging and radiotherapy
SG195545A1 (en) 2008-10-10 2013-12-30 Merck & Cie 18f-labelled folates as pet radiotracers

Also Published As

Publication number Publication date
DK2864329T3 (en) 2019-01-21
ES2703627T3 (es) 2019-03-11
US10357576B2 (en) 2019-07-23
KR20150010970A (ko) 2015-01-29
EP2864329B1 (en) 2018-09-26
US20150125390A1 (en) 2015-05-07
SG11201406481TA (en) 2014-11-27
CA2870124A1 (en) 2013-11-14
EP2864329A1 (en) 2015-04-29
TR201819802T4 (tr) 2019-01-21
CA2870124C (en) 2021-02-16
AU2013258027A1 (en) 2014-11-13
IL235476A0 (en) 2014-12-31
CN104379585A (zh) 2015-02-25
HK1202548A1 (en) 2015-10-02
JP2015516405A (ja) 2015-06-11
JP6198814B2 (ja) 2017-09-20
ZA201407266B (en) 2016-09-28
PL2864329T3 (pl) 2019-03-29
WO2013167653A1 (en) 2013-11-14
PT2864329T (pt) 2019-01-10
KR102116000B1 (ko) 2020-05-29
CN104379585B (zh) 2018-07-06
AU2013258027B2 (en) 2017-11-30
EA201401225A1 (ru) 2015-04-30

Similar Documents

Publication Publication Date Title
ZA201702364B (en) Glucagon analogues
IL237518A0 (en) Glucagon analog
IL235476B (en) Emitter/anti-emitter analogs are marked with f18
PL3181128T3 (pl) Kompozycja farmaceutyczna nilotynibu
EP2822490A4 (en) INTEGRATED IMPLANT
GB2499421B (en) Ramp
PL2722340T3 (pl) Analogi alfa- i gamma-msh
SG11201406860SA (en) Quinazolinedione derivative
ZA201405770B (en) Set-accelerating admixture having improved stability
GB201903206D0 (en) n
PL2873355T3 (pl) Komponent podstawowy
GB201315751D0 (en) Analogues
GB201221388D0 (en) GPS Doll
PL2895117T3 (pl) Stent
PL2888914T3 (pl) Zintegrowana technika wywoływania
GB2505634B (en) Component leg arrangement
GB2508797B (en) Self contained staircase
GB201218696D0 (en) Standing aid
GB201506161D0 (en) Maxu stairs
GB201314742D0 (en) Siv ball
AU342207S (en) Jewelley setting
GB201221028D0 (en) Cushion
GB201210169D0 (en) Seating
PH32012000855S1 (en) Stool
AU343979S (en) Stool

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed